Therapeutic subgroup
N02 – ANALGETIKA
- Anatomical main group N: NERVENSYSTEM
11Decisions
18Patient groups
Added benefit by patient group
- Considerable4
- Minor1
- Not proven13
Subgroups
- N02B ANDERE ANALGETIKA UND ANTIPYRETIKA 2 decisions
- N02C MIGRÄNEMITTEL 9 decisions
Decisions, newest first
- 2026-05-07AttrogyDiflunisalNot proven
- 2025-11-20VyduraRimegepantNot proven
- 2025-11-20VyduraRimegepantNot proven: 2 of 2 patient groups
- 2025-08-21AquiptaAtogepantNot proven: 2 of 2 patient groups
- 2023-10-05RayvowLasmiditanNot proven
- 2023-02-16VyeptiEptinezumabNot proven: 2 of 2 patient groups
- 2021-10-21AimovigErenumabConsiderable
- 2019-11-07AjovyFremanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-09-19EmgalityGalcanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-05-02AimovigErenumabConsiderable
- 2018-11-01SativexExtrakt aus Cannabis sativaMinor
Data status: 2026-10-29